Title KOŠTANI UČINCI ANDROGEN DEPRIVIRAJUĆE TERAPIJE U BOLESNIKA S NEMETASTATSKIM KARCINOMOM PROSTATE Title (english) BONE EFFECTS OF ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH NONMETASTATIC PROSTATE CANCER Author Matea Čatipović Mentor Anela Novak (mentor)Committee member Joško Božić (predsjednik povjerenstva)Committee member Marino Vilović (član povjerenstva)Committee member Tina Tičinović Kurir (član povjerenstva)Granter University of Split Defense date and country 2021, Croatia Scientific / art field, BIOMEDICINE AND HEALTHCARE Abstract Cilj istraživanja: Ciljevi ovog istraživanja su usporediti denzitometrijske parametre koštane mineralne strukture i trabekularne strukture kosti pacijenata s nemetastatskim karcinomom prostate liječene androgen deprivirajućom terapijom s kontrolnom skupinom te procijeniti rizik za nastanak patoloških prijeloma u obje skupine.
Ispitanici i postupci: U istraživanje je bilo uključeno ukupno 20 ispitanika s nemetastatskim karcinomom prostate, od kojih je 10 primilo androgen deprivirajuću terapiju a drugih 10 su bile kontrole. Istraživanje se odvijalo kroz dvije vizite. Prva je vizita bila pri samom uključenju u istraživanje, a druga nakon 3 mjeseca. Uzeta im je anamneza te su prilikom svake vizite zabilježeni antropometrijski parametri uz pomoć Tanita vage te koštani parametri dobiveni denzitometrijom. Zahvaljujući FRAX® alatu procijenjen im je rizik za nastanak prijeloma.
Rezultati: Nakon 3 mjeseca od uključenja u istraživanje pronađene su statistički značajne razlike promatrajući ispitivanu i kontrolnu skupinu. U odnosu na kontrolnu skupinu, ispitivana je skupina imala snižene vrijednosti BMD-a ukupnog područja kuka (P=0,031) i T-score ukupnog područja kuka (P=0,005), dok su 10-godišnja vjerojatnost ozbiljnog osteoporotičnog prijeloma izračunata FRAX® alatom ne uzimajući u obzir BMD (P=0,007) i 10-godišnja vjerojatnost prijeloma kuka izračunata FRAX® alatom ne uzimajući u obzir BMD (P=0,034) bile povišene. Uzimajući u obzir samo ispitivanu skupinu, također nailazimo na statistički značajne razlike nakon 3 mjeseca od početka terapije. U ispitivanoj skupini smanjio se udio tjelesne vode (P=0,037), masa tjelesne vode (P=0,038) i udio mišićne mase (P=0,049). S druge strane, porastao im je udio masti (P=0,047). 10-godišnja vjerojatnost ozbiljnog osteoporotičnog prijeloma izračunata FRAX® alatom ne uzimajući u obzir BMD (P=0,005) i 10-godišnja vjerojatnost prijeloma kuka izračunata FRAX® alatom ne uzimajući u obzir BMD (P=0,005) također su bile povišenih vrijednosti.
Zaključak: U pacijenata s nemetastatskim karcinomom prostate nakon tromjesečne primjene androgen deprivirajuće terapije možemo očekivati smanjenu koštanu mineralnu gustoću, povišen rizik za prijelom kostiju te promjene u tjelesnom sastavu.
Abstract (english) Objectives: The aim of this study was to compare the densitometric parameters of patients with non-metastatic prostate cancer treated with androgen deprivation therapy in relation to the control group and to assess the risk of fractures in both groups.
Subjects and Methods: A total of 20 subjects with non-metastatic prostate cancer were included in the study, of whom 10 received androgen deprivation therapy and the other 10 were controls. The research took place through two visits. The first visit was at the time of inclusion in the study, and the second after 3 months. Their medical histories were taken and during each visit anthropometric parameters were recorded with Tanita scale for measuring body composition and bone parameters obtained by densitometry. Using the FRAX® calculator, their risk of fractures has been estimated.
Results: After 3 months of study inclusion, statistically significant differences were found observing the test and control groups. Compared to the control group, the test group had reduced BMD total hip (P= 0.031) and T-score total hip (P= 0.005), while the 10-year probability of a serious osteoporotic fracture calculated by the FRAX® calculator without taking into account BMD (P = 0.007) and the 10-year probability of hip fracture calculated by the FRAX® calculator without taking into account BMD (P = 0.034) were elevated. Taking into account only the test group, we also encounter statistically significant differences after 3 months from the start of therapy. In the test group, the body water content (P= 0.037), body water mass (P= 0.038) and the muscle content decreased (P= 0.049). On the other hand, their fat content increased (P= 0.047). The 10-year probability of a serious osteoporotic fracture calculated by the FRAX® calculator not taking into account BMD (P = 0.005) and the 10-year probability of hip fracture calculated by the FRAX® calculator not taking into account BMD (P = 0.005) were also elevated.
Conclusions: In patients with non-metastatic prostate cancer after three months of androgen deprivation therapy, we can expect reduced bone mineral density, an increased risk of bone fractures and changes in body composition.
Keywords
Novotvorine prostate
Antagonisti androgena
Antineoplastični agensi
Gustoća kostiju
Keywords (english)
Prostatic Neoplasms
Androgen Antagonists
Antineoplastic Agents
Bone Density
Language croatian URN:NBN urn:nbn:hr:171:554808 Study programme Title: Medicine Type of resource Text File origin Born digital Access conditions Open access Terms of use Created on 2021-07-21 13:10:03
